ACUT
Price
$0.90
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
14.47M
CLRPF
Price
$1.64
Change
-$0.10 (-5.75%)
Updated
Jul 1 closing price
Capitalization
620.87M
Interact to see
Advertisement

ACUT vs CLRPF

Header iconACUT vs CLRPF Comparison
Open Charts ACUT vs CLRPFBanner chart's image
Accustem Sciences
Price$0.90
Change-$0.00 (-0.00%)
Volume$37.67K
Capitalization14.47M
Clarity Pharmaceuticals
Price$1.64
Change-$0.10 (-5.75%)
Volume$500
Capitalization620.87M
ACUT vs CLRPF Comparison Chart in %
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. CLRPF commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and CLRPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ACUT: $0.90 vs. CLRPF: $1.64)
Brand notoriety: ACUT and CLRPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 932% vs. CLRPF: 7%
Market capitalization -- ACUT: $14.47M vs. CLRPF: $620.87M
ACUT [@Biotechnology] is valued at $14.47M. CLRPF’s [@Biotechnology] market capitalization is $620.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • CLRPF’s FA Score: 0 green, 5 red.
According to our system of comparison, ACUT is a better buy in the long-term than CLRPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 4 TA indicator(s) are bullish while CLRPF’s TA Score has 4 bullish TA indicator(s).

  • ACUT’s TA Score: 4 bullish, 4 bearish.
  • CLRPF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CLRPF is a better buy in the short-term than ACUT.

Price Growth

ACUT (@Biotechnology) experienced а +1.58% price change this week, while CLRPF (@Biotechnology) price change was +13.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.35%. For the same industry, the average monthly price growth was +13.82%, and the average quarterly price growth was -0.82%.

Industries' Descriptions

@Biotechnology (+5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLRPF($621M) has a higher market cap than ACUT($14.5M). ACUT YTD gains are higher at: 100.893 vs. CLRPF (-39.372). ACUT has higher annual earnings (EBITDA): -1.42M vs. CLRPF (-66.98M).
ACUTCLRPFACUT / CLRPF
Capitalization14.5M621M2%
EBITDA-1.42M-66.98M2%
Gain YTD100.893-39.372-256%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash36.4KN/A-
Total Debt57.6KN/A-
TECHNICAL ANALYSIS
Technical Analysis
ACUTCLRPF
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
66%
Bearish Trend 5 days ago
69%
Momentum
ODDS (%)
Bearish Trend 5 days ago
85%
Bullish Trend 5 days ago
81%
MACD
ODDS (%)
Bearish Trend 5 days ago
80%
Bullish Trend 5 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
80%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
57%
Aroon
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BDUUY31.44N/A
N/A
Bangkok Dusit Medical Services Public Co., Ltd.
BKUH0.02N/A
N/A
Bakhu Holdings, Corp.
CYSM13.75N/A
N/A
Community Bancorp of Santa Maria
IMQCF5.88N/A
N/A
Inmobiliaria Colonial Socimi SA
WFCNP1.50N/A
N/A
Wells Fargo & Co.

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and LGVN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
N/A
LGVN - ACUT
30%
Poorly correlated
+0.77%
OKYO - ACUT
28%
Poorly correlated
-4.47%
IGMS - ACUT
21%
Poorly correlated
+3.03%
APVO - ACUT
20%
Poorly correlated
N/A
VRNA - ACUT
20%
Poorly correlated
+1.61%
More

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and ENLV have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and ENLV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
N/A
ENLV - CLRPF
22%
Poorly correlated
+4.42%
JBPHF - CLRPF
14%
Poorly correlated
N/A
MLTX - CLRPF
11%
Poorly correlated
+2.15%
TELIF - CLRPF
10%
Poorly correlated
+2.10%
ACUT - CLRPF
9%
Poorly correlated
N/A
More